| Literature DB >> 18462493 |
Jiao Zhao1, Douglas Ridgway, Gordon Broderick, Andriy Kovalenko, Michael Ellison.
Abstract
BACKGROUND: As computational performance steadily increases, so does interest in extending one-particle-per-molecule models to larger physiological problems. Such models however require elementary rate constants to calculate time-dependent rate coefficients under physiological conditions. Unfortunately, even when in vivo kinetic data is available, it is often in the form of aggregated rate laws (ARL) that do not specify the required elementary rate constants corresponding to mass-action rate laws (MRL). There is therefore a need to develop a method which is capable of automatically transforming ARL kinetic information into more detailed MRL rate constants.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18462493 PMCID: PMC2396597 DOI: 10.1186/1752-0509-2-41
Source DB: PubMed Journal: BMC Syst Biol ISSN: 1752-0509
Figure 1Reactions and topology of the . As an example, the pgi pathway described as aggregated rate law (ARL) was replaced by mass-action rate law (MRL) for estimation of the elementary rate constants. The same procedure can be used to estimate rate constants involved in other pathways.
Reaction mechanism and protein abundance for glycolytic pathways of E. coli
| Phosphogluco -isomerase | 1099 | 2.7 | Reversible Uni Uni [51] | G6P + EPGI → EPGI-G6P |
| EPGI-G6P → G6P + EPGI | ||||
| EPGI-G6P → F6P +EPGI | ||||
| F6P + EPGI → EPGI-G6P | ||||
| Phosphofructo -kinase | 3287 | 8.2 | Allosteric regulation and ordered sequential mechanism [39] [52] | ATP + EPFKATR → EPFKAR-ATP |
| EPFKAR-ATP → ATP + EPFKATR | ||||
| F6P + EPFKAR-ATP → EPFKAR-ATP-F6P | ||||
| EPFKAR-ATP-F6P → F6P + EPFKAR-ATP | ||||
| EPFKAR-ATP-F6P → FDP + EPFKAR-ADP | ||||
| EPFKAR-ADP → ADP + EPFKATR | ||||
| Fructose-bisphosphate aldolase | 16326 | 40.5 | Ordered Uni Bi [51] | FDP + EFBA → EFBA-FDP |
| EFBA-FDP → FDP + EFBA | ||||
| EFBA-FDP → GAP + EFBA-DHAP | ||||
| GAP + EFBA-DHAP → EFBA-FDP | ||||
| EFBA-DHAP → DHAP + EFBA | ||||
| DHAP + EFBA → EFBA-DHAP | ||||
| Triosephosphate isomerase | 9106 | 22.6 | Reversible Uni Uni [51] | DHAP + ETPIA → ETPIA-DHAP |
| ETPIA-DHAP → DHAP + ETPIA | ||||
| ETPIA-DHAP → GAP + ETPIA | ||||
| GAP + ETPIA → ETPIA-DHAP | ||||
| Glyceraldehyde 3-phosphate dehydrogenase | 49091 | 121.7 | Ordered sequential mechanism [37] | NAD + EGAP → EGAP-NAD |
| EGAP-NAD → NAD + EGAP | ||||
| GAP + EGAP-NAD → EGAP-NAD-GAP | ||||
| EGAP-NAD-GAP → GAP + EGAP-NAD | ||||
| EGAP-NAD-GAP → PGP + EGAP-NADH | ||||
| PGP + EGAP-NADH → EGAP-NAD-GAP | ||||
| EGAP-NADH → NADH + EGAP | ||||
| NADH + EGAP → EGAP-NADH | ||||
| Phosphoglycerate kinase | 14682 | 36.4 | Ordered sequential mechanism [53] | PGP + EPGK → EPGK-PGP |
| EPGK-PGP → PGP + EPGK | ||||
| ADP + EPGK-PGP → EPGK-PGP-ADP | ||||
| EPGK-PGP-ADP → ADP + EPGK-PGP | ||||
| EPGK-PGP-ADP → ATP + EPGK-PG3 | ||||
| ATP + EPGK-PG3 → EPGK-PGP-ADP | ||||
| EPGK-PG3 → PG3 + EPGK | ||||
| PG3 + EPGK → EPGK-PG3 | ||||
| Phosphoglycerate mutase | 966 | 2.4 | Reversible Uni Uni [21] | PG3 + EPGM → EPGM-PG3 |
| EPGM-PG3 → PG3 + EPGM | ||||
| EPGM-PG3 → PG2 + EPGM | ||||
| PG2 + EPGM → EPGM-PG3 | ||||
| Enolase | 11283 | 28.0 | Reversible Uni Uni [21] | PG2 + EENO → EENO-PG2 |
| EENO-PG2 → PG2 + EENO | ||||
| EENO-PG2 → PEP + EENO | ||||
| PEP + EENO → EENO-PG2 | ||||
| Pyruvate kinase | 500 | 1.2 | Allosteric regulation and ordered sequential mechanism [24, 39] | PEP + EPYKFTR → EPYKFR-PEP |
| EPYKFR-PEP → PEP + EPYKFTR | ||||
| EPYKFR-PEP + ADP → EPYKFR-PEP-ADP | ||||
| EPYKFR-PEP-ADP → EPYKFR-PEP + ADP | ||||
| EPYKFR-PEP-ADP → PYR + EPYKFR-ATP | ||||
| EPYKFR-ATP → ATP + EPYKFTR |
a Protein abundances are taken from mass spectrometry data [34], with the exception of the abundance for pykF which is taken from 2-D gel data [35]
b Volume concentration is calculated based on E. coli cytoplasm volume equivalent to 6.7 × 10-16 L [54]
Summary statistics about rate constants estimated from the proposed hybrid method a,b
| Phosphogluco -isomerase | K1f,PGI*[G6P]*[EPGI] | (1.27 ± 0.00) × 105 | 0.0 | (1.27, 1.27) × 105 | (9.2 ± 2.4) × 10-3 |
| K1r,PGI*[EPGI-G6P] | (1.28 ± 0.00) × 105 | 0.0 | (1.28, 1.28) × 105 | ||
| K2f,PGI*[EPGI-G6P] | (2.41 ± 0.00) × 105 | 0.0 | (2.41, 2.41) × 105 | ||
| K2r,PGI*[F6P]*[EPGI] | (1.39 ± 0.01) × 106 | 0.0 | (1.39, 1.39) × 106 | ||
| Phosphofructo -kinase | K1f,PFKA* | (4.21 ± 0.63) × 101 | 15.0 | (3.83, 4.59) × 101 | (5.4 ± 1.2) × 10-2 |
| K1r,PFKA*[EPFKAR-ATP] | (1.73 ± 1.94) × 100 | 112.7 | (0.55, 2.90) × 100 | ||
| K2f,PFKA*[EPFKAR-ATP]*[F6P]n | (4.70 ± 0.50) × 103 | 10.7 | (4.39, 5.00) × 103 | ||
| K2r,PFKA*[EPFKAR-ATP-F6P] | (6.52 ± 7.93) × 101 | 121.6 | (1.73, 11.31)×101 | ||
| K3f,PFKA*[EPFKAR-ATP-F6P] | (3.50 ± 0.76) × 102 | 21.8 | (3.05, 3.96) × 102 | ||
| K4f,PFKA*[EPFKAR-ADP] | (3.67 ± 3.01) × 105 | 82.2 | (1.85, 5.49) × 105 | ||
| Fructose- bisphosphate aldolase | K1f,FBA*[FDP]*[EFBA] | (4.98 ± 0.01) × 103 | 0.2 | (4.98, 4.98) × 103 | (4.8 ± 0.1) × 10-3 |
| K1r,FBA*[EFBA-FDP] | (9.14 ± 0.02) × 102 | 0.2 | (9.13, 9.14) × 102 | ||
| K2f,FBA*[EFBA-FDP] | (4.33 ± 0.00) × 102 | 0.0 | (4.33, 4.33) × 102 | ||
| K2r,FBA*[GAP]*[EFBA-DHAP] | (9.98 ± 0.02) × 104 | 0.2 | (9.98, 9.99) × 104 | ||
| K3f,FBA*[EFBA-DHAP] | (5.95 ± 0.01) × 104 | 0.2 | (5.94, 5.95) × 104 | ||
| K3r,FBA*[DHAP]*[EFBA] | (1.04 ± 0.00) × 104 | 0.0 | (1.04, 1.04) × 104 | ||
| Triosephosphate isomerase | K1f,TPIA*[DHAP]*[ETPIA] | (1.17 ± 0.00) × 103 | 0.0 | (1.17, 1.17) × 103 | (1.5 ± 0.6) × 10-4 |
| K1r,TPIA*[ETPIA-DHAP] | (2.34 ± 0.00) × 102 | 0.0 | (2.34, 2.34) × 102 | ||
| K2f,TPIA*[ETPIA-DHAP] | (3.04 ± 0.00) × 103 | 0.0 | (3.04, 3.04) × 103 | ||
| K2r,TPIA*[GAP]*[ETPIA] | (1.09 ± 0.00) × 104 | 0.0 | (1.09, 1.09) × 104 | ||
| Glyceraldehyde 3- phosphate dehydrogenase | K1f,GAP*[NAD]*[EGAP] | (3.01 ± 0.00) × 104 | 0.0 | (3.01, 3.01) × 104 | (7.8 ± 0.4) × 10-2 |
| K1r,GAP*[EGAP-NAD] | (7.57 ± 0.00) × 103 | 0.0 | (7.57, 7.57) × 103 | ||
| K2f,GAP*[GAP]*[EGAP-NAD] | (1.85 ± 0.25) × 104 | 13.5 | (1.75, 1.95) × 104 | ||
| K2r,GAP*[EGAP-NAD-GAP] | (9.61 ± 0.90) × 105 | 9.4 | (9.25, 9.96) × 105 | ||
| K3f,GAP*[EGAP-NAD-GAP] | (1.67 ± 0.83) × 106 | 50.0 | (1.34, 2.00) × 106 | ||
| K3r,GAP*[PGP]*[EGAP-NADH] | (1.99 ± 0.64) × 109 | 32.3 | (1.74, 2.24) × 109 | ||
| K4f,GAP*[EGAP-NADH] | (7.61 ± 0.01) × 103 | 0.2 | (7.61, 7.62) × 103 | ||
| K4r,GAP*[NADH]*[EGAP] | (7.36 ± 0.13) × 10-1 | 0.2 | (7.35, 7.37) × 10-1 | ||
| Phosphoglycerate kinase | K1f,PGK*[PGP]*[EPGK] | (1.77 ± 0.00) × 106 | 0.0 | (1.77, 1.77) × 106 | (3.4 ± 1.4) × 10-3 |
| K1r,PGK*[EPGK-PGP] | (8.30 ± 0.00) × 104 | 0.0 | (8.30, 8.30) × 104 | ||
| K2f,PGK*[ADP]*[EPGK-PGP] | (4.58 ± 0.05) × 105 | 0.0 | (4.57, 4.60) × 105 | ||
| K2r,PGK*[EPGK-PGP-ADP] | (4.52 ± 0.35) × 103 | 7.8 | (4.41, 4.63) × 103 | ||
| K3f,PGK*[EPGK-PGP-ADP] | (3.47 ± 3.45) × 105 | 99.5 | (2.36, 4.57) × 105 | ||
| K3r,PGK*[ATP]*[EPGK-PG3] | (5.10 ± 4.99) × 105 | 97.9 | (3.50, 6.69) × 105 | ||
| K4f,PGK*[EPGK-PG3] | (1.64 ± 0.88) × 105 | 53.6 | (1.36, 1.92) × 105 | ||
| K4r,PGK*[PG3]*[EPGK] | (1.24 ± 0.68) × 105 | 54.7 | (1.03, 1.46) × 105 | ||
| Phosphoglycerate Mutase | K1f,PGM*[PG3]*[EPGM] | (2.01 ± 0.00) × 106 | 0.0 | (2.01, 2.01) × 106 | (2.8 ± 1.3) × 10-2 |
| K1r,PGM*[EPGM-PG3] | (3.64 ± 0.00) × 105 | 0.0 | (3.64, 3.64) × 105 | ||
| K2f,PGM*[EPGM-PG3] | (3.71 ± 0.00) × 104 | 0.0 | (3.71, 3.71) × 104 | ||
| K2r,PGM*[PG2]*[EPGM] | (1.08 ± 0.01) × 106 | 1.3 | (1.07, 1.09) × 106 | ||
| Enolase | K1f,ENO*[PG2]*[EENO] | (1.42 ± 0.00) × 105 | 0.0 | (1.42, 1.42) × 105 | (2.6 ± 1.2) × 10-2 |
| K1r,ENO*[EENO-PG2] | (2.37 ± 0.00) × 103 | 0.0 | (2.37, 2.37) × 103 | ||
| K2f,ENO*[EENO-PG2] | (1.18 ± 0.00) × 104 | 0.0 | (1.18, 1.18) × 104 | ||
| K2r,ENO*[PEP]*EENO] | (1.05 ± 0.02) × 105 | 1.9 | (1.05, 1.06) × 105 | ||
| Pyruvate kinase | K1f,PYKF* | (1.59 ± 0.00) × 102 | 0.0 | (1.59, 1.59) × 102 | (6.0 ± 2.0) × 10-4 |
| K1r,PYKF*[EPYKFR-PEP] | (4.96 ± 0.17) × 101 | 3.4 | (4.89, 5.03) × 101 | ||
| K2f,PYKF*[EPYKFR-PEP]*[ADP] | (4.58 ± 2.92) × 102 | 63.9 | (3.37, 5.78) × 102 | ||
| K2r,PYKF*[EPYKFR-PEP-ADP] | (2.43 ± 1.85) × 102 | 76.2 | (1.67, 3.19) × 102 | ||
| K3f,PYKF*[EPYKFR-PEP-ADP] | (2.71 ± 1.71) × 102 | 63.2 | (2.00, 3.41) × 102 | ||
| K4f,PYKF*[EPYKFR-ATP] | (7.89 ± 3.09) × 101 | 39.2 | (6.61, 9.16) × 101 |
a Rate constants are the statistical solutions from 25 optimization runs which were performed with different random initial guesses for parameters of an individual enzyme. Through hybrid MRL/ARL model, MRL parameters for each enzyme are estimated in separate steps. Units are mM-1 s-1 and s-1 for second and first-order rate constants, respectively.
b SD: Standard deviation; CV: Coefficient of variation; CI: Confidence interval; fval: cost function value.
c Due to uncertainty in the source data [21], we have truncated to three digits, regarding of SD.
d Reaction orders for allosteric enzyme pfkA are non-integer with respect to ATP and F6P, allowing for fractal properties [43] due to enzyme conformational changes. Values of m and n are 5.19 ± 0.28 and 9.80 ± 0.41, respectively, after optimization.
e Reaction for allosteric enzyme pyruvate kinase is first order with respect to PEP and ADP, according to Tormonia's paper [39]
Figure 2Allosteric enzymes consisting of an allosteric segment (dark shaded area) and an enzymatic reaction segment. (A): Pyruvate kinase, where the number of allosteric sites and catalytic sites are 4 and 1, respectively [39]. (B): Phosphofructokinase, where the number of allosteric sites is 2 according to [39]. Non-integral reaction orders are assumed for two substrates due to fractal properties caused by enzyme conformational changes [43].
Effect of uncertainty in pykF enzyme concentration measurement on rate constants estimation a
| 1.59 ± 0.00 | [1.59, 1.59] | 0 | 1.61 ± 0.17 | [1.54, 1.68] | 1.3 | 1.51 ± 0.21 | [1.42, 1.60] | 5.0 | |
| 0.50 ± 0.02 | [0.49, 0.50] | 0 | 0.50 ± 0.06 | [0.47, 0.52] | 0 | 0.47 ± 0.07 | [0.44, 0.50] | 6.0 | |
| 4.58 ± 2.92 | [3.37, 5.78] | 0 | 4.61 ± 3.76 | [3.05, 6.16] | 0.7 | 4.52 ± 2.47 | [3.50, 5.54] | 1.3 | |
| 2.43 ± 1.85 | [1.67, 3.19] | 0 | 1.96 ± 1.76 | [1.24, 2.69] | 19.3 | 2.62 ± 1.71 | [1.90, 3.32] | 7.8 | |
| 2.71 ± 1.71 | [2.00, 3.41] | 0 | 2.69 ± 1.63 | [2.02, 3.36] | 0.7 | 2.70 ± 1.51 | [2.08, 3.32] | 0.4 | |
| 0.79 ± 0.31 | [0.66, 0.92] | 0 | 0.89 ± 0.56 | [0.66, 1.12] | 12.7 | 0.66 ± 0.19 | [0.58, 0.74] | 16.5 | |
a SD: Standard deviation; CI: Confidence interval; RE: Relative errors compared to 0% noise case.
b Rate constants are the statistical solutions from 25 optimization runs which were performed with random initial guesses for parameters of pykF.
c Rate constants are the statistical solutions from 25 optimization runs which were performed with random initial guesses for parameters and with Gaussian noise added to the experimentally determined pykF concentration.
Figure 3Sensitivity analysis of the flux through glycolysis with respect to rate constants along . See Figure 4A for the reaction mechanism of gapA pathway.
Figure 4Alternative reaction mechanisms of the Glyceraldehyde 3-phosphate dehydrogenase (. A: Ordered Bi-Bi system with stable central ternary complex. B: Theorell-Chance Bi-Bi system with only the formation of stable binary complex.
Figure 5Simulated dynamics of metabolites interacting between glycolysis and pentose phosphate pathway (PPP). A: glycolytic metabolites. B: PPP metabolites. MRL simulation: dotted line; ARL simulation: solid line. The time period over which we run the simulation is consistent with real experiments wherein all the intracellular metabolites could be sampled and measured within 20 seconds after glucose impulse [21].
Figure 6A flow chart illustrating the process of extracting MRL constants from ARL models. SMKA: Schematic Method of King and Altman; GRC: General Rule of Cleland; SA: simulated annealing algorithm.